Annual revenue fell from KRW 64.5 billion in 2022 to KRW 36 billion in 2023, a 44.1% decline, then rose to KRW 36.5 billion in 2024 (up 1.2%) and fell to KRW 34.6 billion in 2025 (down 5.2%). 2022 was the largest year and 2025 the smallest in the 2022 to 2025 range.
The company attributed the weak 2023 to the end of the PEET pharmacist exam. Operating profit went from KRW 2 billion in 2022 to an operating loss of KRW 3.94 billion in 2023, then back to an operating profit of KRW 2.24 billion in 2024 and KRW 1.81 billion in 2025 (down 18.9%).
Operating margin was 3.1% in 2022, -10.9% in 2023, 6.1% in 2024 and 5.2% in 2025. The company linked the 2024 return to profit to cost reductions from a restructured business.
Controlling shareholders' net profit went from a net loss of KRW 3.2 billion in 2023 to KRW 3.78 billion in 2024 and KRW 2.79 billion in 2025 (down 26.3%). Net profit including non-controlling interests is disclosed at the same yearly amounts.
By quarter, the third quarter of 2025 posted revenue of KRW 9.32 billion and operating profit of KRW 1.67 billion; the fourth quarter swung to revenue of KRW 7.13 billion (down 23.5% from the prior quarter) and an operating loss of KRW 570 million.
The first quarter of 2026 returned to operating profit of KRW 150 million on revenue of KRW 7.78 billion. Second-quarter revenue reached KRW 9.01 billion (up 15.8% quarter on quarter) with operating profit of KRW 995 million.
Third-quarter revenue of KRW 8.75 billion was down 2.9% quarter on quarter and down 6.2% year on year, while operating profit of KRW 1.05 billion was up 5.3% quarter on quarter but down 37.2% year on year.
Controlling shareholders' net profit peaked at KRW 1.89 billion in the first quarter of 2026 and then fell to KRW 1.59 billion and KRW 1.35 billion. Operating cash flow stayed positive from 2023 to 2025, at KRW 1.05 billion, KRW 8.39 billion and KRW 5.1 billion.
The reason for the fourth-quarter 2025 loss cannot be pinned down from the disclosed figures alone, so the notes in the next annual report are the place to check it.